

#6

The information in this facsimile is confidential and is intended for the sole use of the addressee designated below. If this facsimile has been misdirected, kindly return it by postal service to Gilead Sciences, Inc. If you do not receive all pages clearly, please telephone (650) 573-4709 or 572-6535.

GILEAD SCIENCES, INC.
333 Lakeside Drive
Foster City, California 94404
Telephone: 650/572-6535 or 650/574-3000
Telefacsimile: 650/573-4899 (Patents) or 650/578-9264

Date: April 10, 1998 Telefax: (703) 308-7921

To: Assistant Commissioner Re: In re application of: Arimilli et al
for Patents Serial No.: 08/900,746
Washington, D.C. 20231 Filed: July 25, 1997

Attorney Docket No. 221.P1
Group No. 1613
Examiner: M. Ambrose

For: NUCLEOTIDE ANALOGS

From: Daryl D. Muenchau, Reg. 36,616

Daryl D Muenchau

Total Number of Pages Including Cover Sheet: 53

Certification of Facsimile Transmission

I hereby certify that this paper along with the following documents are being facsimile transmitted to the Patent and Trademark Office and that the original documents are being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on the date shown below.

Transmittal of Information Disclosure Statement
Information Disclosure Statement
Copies of 3 cited references

Robin Torres

Type or print name of person signing certification

Robin Torres
Signature

April 10, 1998
Date

Attorney Docket No. 221.P1
PATENT**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**In re application of: Arimilli et al.Serial No.: 08/900,746Group No.: 1613Filed: July 25, 1997Examiner: M. AmbroseFor: NUCLEOTIDE ANALOGS**Assistant Commissioner for Patents****Washington, D.C. 20231****TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT WITHIN
THREE MONTHS OF FILING OR BEFORE MAILING OF
FIRST OFFICE ACTION (37 CFR 1.97 (b))****CERTIFICATE OF MAILING**

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited on the date shown below with the United States Postal Service in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

(check and complete appropriate item below);

☒ 37 CFR 1.8 (a)
with sufficient postage as
first class mail

or

☐ 37 CFR 1.10
as "Express Mail Post
Office to Addressee" Mailing
Label
No. _____

Date: April 10, 1998

Robin Torres
(Type or print name of person mailing paper)

Robin Torres
(Signature of person mailing paper)

**IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT**

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97 (b).

Reg. No. 36,616

Tel. No.: (650) 573-4712

Daryl D Muenchau
SIGNATURE OF AGENT

Daryl D. Muenchau
Type or print name of agent

Gilead Sciences, Inc.
333 Lakeside Drive
P.O. Address

Foster City, CA 94404

Attorney Docket No. 221.P1
PATENT**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**In re application of: **Arimilli et al.**Serial No.: **08/900,746**Group No.: **1613**Filed: **July 25, 1997**Examiner: **M. Ambrose**For: **NUCLEOTIDE ANALOGS**

#6

Assistant Commissioner for Patents
Washington, D.C. 20231**INFORMATION DISCLOSURE STATEMENT (modified)****List of Sections Forming Part of This Information Disclosure Statement.**

The following sections are being submitted for this Information Disclosure Statement:

1. ☒ Preliminary Statements
2. ☒ FORM PTO - 1449 (Modified)
3. ☒ Copies of Listed Information Items Accompanying This Statement

Section 1. Preliminary statements

Applicants submit herewith patents, publications or other information of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 CFR 1.97 (g)), an admission that the information cited is, or is considered to be, material to patentability or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Date: April 10, 1998Robin Torres
(Type or print name of person mailing paper)*Robin Torres*
(Signature of person mailing paper)

Section 3. Copies of Listed Information Items Accompanying This Statement

Legible copies of all items listed in Form PTO-1449 accompany this information statement.

Reg. No. 36,616

Daryl D Muenchau
SIGNATURE OF AGENT

Tel. No.: (650) 573-4712

Daryl D. Muenchau
Type or print name of agent

Gilead Sciences, Inc.
333 Lakeside Drive
P.O. Address

Foster City, CA 94404